SCHEMBL8075433

SCHEMBL8075433

CCc1ccccc1C(=O)c1cc(C(C)C)c(O)c(C(C)C)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 3/20 0.62
GABRB1 P18505 2/20 0.62
BCL2 P10415 3/20 0.54
MCL1 Q07820 2/20 0.54
GAA P10253 3/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
HSP90AB1 P08238 4/20 0.43
HSP90AA1 P07900 1/20 0.39
GLRA1 P23415 1/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
GABRB2 P47870 2/20 0.39
SLC6A2 P23975 2/20 0.39
PTGS1 P23219 2/20 0.39
FAAH O00519 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11326985 0.83 GABRA1 (0.68) GABRA1GABRB1BCL2MCL1GAA
SCHEMBL8080592 0.82 GABRA1 (0.58) GABRA1GABRB1BCL2MCL1GAA
SCHEMBL11758041 0.81 GABRA1 (0.71) GABRA1GABRB1BCL2MCL1GAA
SCHEMBL8077329 0.81 GABRA1 (0.66) GABRA1GABRB1BCL2MCL1GAA
SCHEMBL8077318 0.80 GABRA1 (0.64) GABRA1GABRB1BCL2MCL1GAA
SCHEMBL8067388 0.80 GABRA1 (0.64) GABRA1GABRB1BCL2MCL1GAA
SCHEMBL8081926 0.80 GABRA1 (0.64) GABRA1GABRB1BCL2MCL1GAA
SCHEMBL8075421 0.80 GABRA1 (0.64) GABRA1GABRB1BCL2MCL1GAA
SCHEMBL8077077 0.78 GABRA1 (0.60) GABRA1GABRB1BCL2MCL1GAA
SCHEMBL13639480 0.78 GABRA1 (0.60) GABRA1GABRB1BCL2MCL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2520290-B1 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE LLC (US) 2014-12-10 EP disclosed
US-7586008-B2 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2009-09-08 US disclosed
US-7586008-B2 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2009-09-08 US disclosed
US-20080275100-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC. (US) 2008-11-06 US disclosed
US-20080275100-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC. (US) 2008-11-06 US disclosed
US-20070185217-A1 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2007-08-09 US disclosed
US-20070185217-A1 Propofol analogs, process for their preparation, and methods of use ABRAXIS BIOSCIENCE, INC. (US) 2007-08-09 US disclosed
WO-2005063665-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE ABRAXIS BIOSCIENCE, INC (US) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275100-A1 PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE CYP3A5, CYP3A4, GABARAP GABRA1 32/4885GABRB1 81/4885BCL2 4801/4885
US-20070185217-A1 Propofol analogs, process for their preparation, and methods of use CYP3A5, CYP3A4, GABARAP GABRA1 32/4885GABRB1 81/4885BCL2 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.